23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

C. Watera; J. Nakiyingi; G. Miiro; R. Muwonge; J. A. G. Whitworth; C.F. Gilks; Neil French

doi:10.1097/00002030-200405210-00018

23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

C. Watera, J. Nakiyingi, G. Miiro, R. Muwonge, J. A. G. Whitworth, C.F. Gilks, Neil French

Liverpool School of Tropical Medicine

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Article › peer-review

65 Citations (Scopus)

Abstract

23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

Original language	English
Pages (from-to)	1210-1213
Number of pages	4
Journal	AIDS
Volume	18
Issue number	8
DOIs	https://doi.org/10.1097/00002030-200405210-00018
Publication status	Published - 21 May 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00002030-200405210-00018

Cite this

@article{ae4758506c704f2b855eef598faab445,

title = "23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort",

abstract = "23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95\% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.",

author = "C. Watera and J. Nakiyingi and G. Miiro and R. Muwonge and Whitworth, \{J. A. G.\} and C.F. Gilks and Neil French",

year = "2004",

month = may,

day = "21",

doi = "10.1097/00002030-200405210-00018",

language = "English",

volume = "18",

pages = "1210--1213",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

AU - Watera, C.

AU - Nakiyingi, J.

AU - Miiro, G.

AU - Muwonge, R.

AU - Whitworth, J. A. G.

AU - Gilks, C.F.

AU - French, Neil

PY - 2004/5/21

Y1 - 2004/5/21

N2 - 23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

AB - 23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed a persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.

U2 - 10.1097/00002030-200405210-00018

DO - 10.1097/00002030-200405210-00018

M3 - Article

SN - 0269-9370

VL - 18

SP - 1210

EP - 1213

JO - AIDS

JF - AIDS

IS - 8

ER -

23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this